Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20886923 | 0.90 | SIGMAR1 (0.54) | SIGMAR1GAANPC1RAB9ATSPO | |
| SCHEMBL29666490 | 0.85 | SIGMAR1 (0.67) | SIGMAR1GAANR4A1NR4A2NR4A3 | |
| SCHEMBL1614544 | 0.85 | SIGMAR1 (0.67) | SIGMAR1GAANR4A1NR4A2NR4A3 | |
| SCHEMBL11872011 | 0.83 | SIGMAR1 (0.65) | SIGMAR1GAANR4A1NR4A2NR4A3 | |
| SCHEMBL8150820 | 0.83 | SIGMAR1 (0.65) | SIGMAR1GAANPC1RAB9AKDM4E | |
| SCHEMBL10943508 | 0.83 | SIGMAR1 (0.65) | SIGMAR1GAANR4A1NR4A2NR4A3 | |
| SCHEMBL1839015 | 0.83 | SIGMAR1 (0.65) | SIGMAR1GAAKDM4E | |
| SCHEMBL28259034 | 0.83 | SIGMAR1 (0.65) | SIGMAR1GAANR4A1NR4A2NR4A3 | |
| SCHEMBL11024265 | 0.82 | GAA (0.77) | SIGMAR1GAANPC1RAB9AKDM4E | |
| SCHEMBL31425728 | 0.82 | SIGMAR1 (0.59) | SIGMAR1GAANPC1RAB9ANR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0786483-B1 | Process for an activated anionic lactam polymerisation | INVENTA AG (CH) | 2000-04-19 | — | — | EP | claimed |
| US-5756647-A | LIQUID SYSTEM: CATALYST, ACTIVATOR AND SOLVENT | EMS-INVENTA AG (CH) | 1998-05-26 | — | — | US | claimed |
| US-5730996-A | Intercalates and expoliates formed with organic pesticide compounds and compositions containing the same | AMCOL INTERNATIONAL CORPORATION (US) | 1998-03-24 | — | — | US | claimed |
| EP-0786483-A2 | Process for an activated anionic lactam polymerisation | EMS-INVENTA AG (CH) | 1997-07-30 | — | — | EP | claimed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| WO-2021152149-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2021-08-05 | — | — | WO | disclosed |
| CN-105960402-A | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| US-20140116112-A1 | METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF CONTAMINANTS IN A SAMPLE | K & D LABORATORIES, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | Wurster, Siegfried (FI) | 2010-02-25 | — | — | US | disclosed |
| CN-101500410-A | Granular controlled release agrochemical compositions and process for preparing same | OMS INVEST INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-1885693-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | Wurster, Siegfried (FI) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123020-A1 | PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4 | JUVANTIA PHARMA LTD OY (FI) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006074261-A2 | METHOD AND COMPOSITIONS FOR CONTROLLING RELEASE OF ORGANIC COMPOSITIONS | MICHIGAN STATE UNIVERSITY (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-0786482-B1 | Liquid system for the anionic lactam polymerisation | INVENTA AG (CH) | 2000-08-16 | — | — | EP | disclosed |
| US-5955094-A | INTERCALATING A PHYLLOSILICATE WITH A PESTICIDE | AMCOL INTERNATIONAL CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5760164-A | STORAGE STABILITY | EMS-INVENTA AG (CH) | 1998-06-02 | — | — | US | disclosed |
| US-5730996-A | Intercalates and expoliates formed with organic pesticide compounds and compositions containing the same | AMCOL INTERNATIONAL CORPORATION (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0808568-A1 | Intercalates and exfoliates formed with organic pesticide compounds and compositions containing the same | AMCOL INTERNATIONAL CORPORATION (US) | 1997-11-26 | — | — | EP | disclosed |
| CN-1161977-A | Liquid-phase system. for polymerization of anionic lactam | INVENTA AG (CH) | 1997-10-15 | — | — | CN | disclosed |
| EP-0786482-A2 | Liquid system for the anionic lactam polymerisation | EMS-INVENTA AG (CH) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048549-A1 | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | SSTR1, SSTR4, SSTR3 | SIGMAR1 429/4885GAA 3279/4885NPC1 3322/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | SIGMAR1 4731/4885GAA 1345/4885NPC1 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.